OncoMatch/Clinical Trials/NCT06658405
Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical Lesions
Is NCT06658405 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Human Papillomavirus 9-valent Vaccine, Recombinant for cervical lesion.
Treatment: Human Papillomavirus 9-valent Vaccine, Recombinant — This is a single-center, Phase II interventional study evaluating secondary HPV vaccination after treatment of high-grade cervical lesions. The study aims to estimate the rate of HPV clearance within two years following an initial positive HPV control test in women over 45 years of age who are chronic HPV carriers and have undergone treatment for high-grade intraepithelial cervical lesions, and who receive HPV vaccination. The study includes two cohorts: 1. Eligible patients who consent to vaccination will participate in a prospective, single-center, single-arm, interventional clinical trial (Category 2). 2. Non-vaccinated patients will be included in a non-interventional observational study, with no changes to their standard care.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Disease stage
Grade: high-grade
high-grade cervical epithelial lesion
Demographics
Prior therapy
Must have received: conization
Patient treated by conization for high-grade cervical epithelial lesion
Cannot have received: HPV vaccination
History of primary HPV vaccination
Cannot have received: HPV-induced invasive cancer
History of HPV-induced invasive cancer (cervical, vaginal, vulvar, anal, oropharyngeal cancer)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06658405 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior HPV vaccination, HPV-induced invasive cancer disqualifies patients from enrollment.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify